Johnson & Johnson Acquires Cardiovascular Specialist V-Wave

Johnson & Johnson (New Brunswick, NJ, USA) has entered into a definitive agreement to acquire V-Wave Ltd. (Caesarea, Israel) which is focused on developing innovative treatment options for patients with heart failure. Under the terms of the agreement, Johnson & Johnson will acquire V-Wave for an upfront payment of USD 600 million, subject to customary adjustments, with the potential for additional regulatory and commercial milestone payments up to approximately USD 1.1 billion. V-Wave will join Johnson & Johnson as part of Johnson & Johnson MedTech.

V-Wave’s cardiovascular implant technology specifically targets heart failure with reduced ejection fraction (HFrEF) wherein a patient’s heart muscle has insufficient ability to pump blood containing oxygen and nutrients to the body. V-Wave’s Ventura Interatrial Shunt (IAS) is a novel implantable device designed to reduce elevated left atrial pressure found in congestive heart failure by creating a shunt between the left and right atrium, thus minimizing cardiovascular events and heart failure hospitalizations. The device is placed in the heart through a minimally invasive catheter-based procedure and has the potential to fill a significant treatment gap between guideline-directed medical therapies (GDMT) as a first-line therapy and highly invasive cardiac replacement therapies, including left ventricular assist devices (LVADs) and heart transplantation.

V-Wave’s Ventura IAS received FDA Breakthrough Device Designation in 2019 and the CE mark in 2020 and has the potential to be the first device of its kind to market. The device addresses an unmet need for approximately 800,000 patients who experience HFrEF in the U.S. every year, representing a market opportunity for significant sustainable growth and meaningful impact. The planned acquisition of V-Wave will extend Johnson & Johnson MedTech’s position as an innovation leader in addressing cardiovascular disease. It will further accelerate its shift into high-growth and high-opportunity markets and will deepen its relationships with structural interventional cardiologists and heart failure specialists.

“We are excited to welcome V-Wave to Johnson & Johnson MedTech and to take another meaningful step toward transforming the standard of care for cardiovascular disease. We recognize the importance of identifying more diverse and effective treatments for heart failure, and our recent track record demonstrates our focus on accelerating our impact on the most urgent and pressing unmet needs,” said Tim Schmid, Executive Vice President and Worldwide Chairman of Johnson & Johnson MedTech. “We know V-Wave well, with our relationship dating back to our original investment in the company in 2016, and we have a deep understanding of the technology and science, as well as the company’s commitment to patients. We look forward to working with the V-Wave team at this pivotal stage of its evolution to bring the Ventura Interatrial Shunt technology to patients.”

“At V-Wave, we are dedicated to achieving our vision to help patients around the world – and we know Johnson & Johnson MedTech shares this mission,” added Dr. Neal Eigler, Chief Executive Officer of V-Wave. “We are confident that Johnson & Johnson MedTech is well-positioned to ensure V-Wave’s breakthrough ideas and technology reach patients in need as quickly and effectively as possible. I couldn’t be prouder of the V-Wave team, and the commitment it has taken to achieve this milestone. We look forward to continuing to build a world where cardiovascular disease is prevented, treated, and cured.”

Related Links:
Johnson & Johnson
V-Wave Ltd.